| Excerpt | Relevance | Reference |
|---|
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 7.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |
| "This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment." | 3.88 | Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. ( Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K, 2018) |